2015-11-12T13:58:14-06:00 2014-12-31 560747981 DIXON HUGHES GOODMAN LLP 111 ROCKVILLE PIKE 6TH FLOOR ROCKVILLE MD 20850 990 2014-01-01 521986675 FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH INC FOUN 3014025311 9650 ROCKVILLE PIKE NO 3411 BETHESDA MD 20814 MARIA FREIRE PHD PRESIDENT 3014025311 2015-11-11 1 LORI K COCHRAN CPA P00853221 2404033700 2014 2016-03-07 17:11:31Z MARIA FREIRE PHD 9650 ROCKVILLE PIKE NO 3411 BETHESDA MD 20814 145938597 0 X HTTP://WWW.FNIH.ORG X 2001 MD THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH WAS ESTABLISHED BY THE UNITED STATES CONGRESS TO SUPPORT THE NIH IN ITS MISSION TO IMPROVE HEALTH, BY FORMING AND FACILITATING PUBLIC-PRIVATE PARTNERSHIPS FOR BIOMEDICAL RESEARCH AND TRAINING. THE FOUNDATION BUILDS PARTNERSHIP FOR DISCOVERY AND INNOVATION TO IMPROVE HEALTH. 31 30 49 0 0 0 59135001 73905546 333361 197177 199587 148518 150775 199253 59818724 74450494 40276784 57340984 0 0 5820510 5868172 0 0 126016 14736567 10868336 60833861 74077492 -1015137 373002 101581045 99015541 10442627 7446160 91138418 91569381 X SEE SCHEDULE O, STATEMENT OF ORGANIZATION'S PRIMARY EXEMPT PURPOSE STATEMENT 0 0 68198142 55844351 197177 SEE SCHEDULE O, PROGRAM ONE, RESEARCH PARTNERSHIPS 1605067 1339808 SEE SCHEDULE O, PROGRAM TWO, FELLOWSHIPS AND TRAINING PROGRAMS 103421 SEE SCHEDULE O, PROGRAM THREE, CAPITAL PROJECTS 427057 156825 SEE SCHEDULE O, MEMORIALS, AWARDS AND EVENTS 427057 156825 70333687 1 1 0 0 0 1 0 0 1 1 1 1 0 0 1 1 1 0 0 0 1 1 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 41 0 1 49 1 0 0 0 0 0 0 0 0 X 31 30 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD VA NY AL AK AZ AR CA CO CT FL GA HI IL KS KY ME MA MI MS MN NH NJ NM NC ND OH OK OR PA RI SC TN UT WA WV WI X X JULIE TUNE 3014025311 9650 ROCKVILLE PIKE BETHESDA MD 20814 ANN LURIE BOARD MEMBER 0.50 X 0 0 0 ANNE WOJCICKI BOARD MEMBER 0.50 X 0 0 0 CHARLES A SANDERS MD CHAIRMAN 2.00 X 0 0 0 EDISON T LIU MD PHD BOARD MEMBER 0.50 X 0 0 0 ELLEN V SIGAL PHD BOARD MEMBER 0.50 X 0 0 0 FREDA C LEWIS-HALL MD BOARD MEMBER 0.50 X 0 0 0 GARRY A NEIL MD BOARD MEMBER 0.50 X 0 0 0 JAMES H DONOVAN BOARD MEMBER 0.50 X 0 0 0 JILLIAN SACKLER BOARD MEMBER 0.50 X 0 0 0 JOEL S MARCUS BOARD MEMBER 0.50 X 0 0 0 JOHN EDWARD PORTER VICE CHAIRMAN, POLICY 1.50 X 0 0 0 JOSEPH M FECZKO MD BOARD MEMBER 0.50 X 0 0 0 KATHY BLOOMGARDEN BOARD MEMBER 0.50 X 0 0 0 LILY SAFRA BOARD MEMBER 0.50 X 0 0 0 LUTHER W BRADY MD HONORARY DIRECTOR 0.50 X 0 0 0 MARTIN J MURPHY JR MD BOARD MEMBER 0.50 X 0 0 0 MILES GILBURNE BOARD MEMBER 0.50 X 0 0 0 MR STEVEN C MAYER TREASURER 1.50 X 0 0 0 MRS WILLIAM MCCORMICK BLAIR JR SECRETARY 1.00 X 0 0 0 MRS WILLIAM N CAFRITZ BOARD MEMBER 0.50 X 0 0 0 NINA SOLARZ BOARD MEMBER 0.50 X 0 0 0 PATRICK C WALSH MD HONORARY DIRECTOR 0.50 X 0 0 0 PAUL BERG PHD DIRECTOR EMERITUS 0.50 X 0 0 0 PAUL L HERRLING PHD BOARD MEMBER 0.50 X 0 0 0 PAUL M MONTRONE PHD BOARD MEMBER 1.00 X 0 0 0 RONALD L KRALL MD BOARD MEMBER 0.50 X 0 0 0 SAMUEL O THIER MD BOARD MEMBER 0.50 X 0 0 0 SHERRY LANSING BOARD MEMBER 0.50 X 0 0 0 SOLOMON H SNYDER MD VICE CHAIRMAN, SCIENCE 1.50 X 0 0 0 STEVEN M PAUL MD BOARD MEMBER 0.50 X 0 0 0 MARIA FREIRE PHD PRESIDENT 40.00 X 374138 0 26000 ANDREA BARUCHIN SR ADVISOR TO PRESIDENT 40.00 X 199543 0 25250 ANN ASHBY DEPUTY EXECUTIVE DIRECTOR 40.00 X 210755 0 32595 DAVID WHOLLEY DIR RESEARCH PARTNERSHIPS 40.00 X 284891 0 37520 JULIA WOLF-RODDA DIR DEVELOPMENT 40.00 X 187834 0 30303 JULIE TUNE CHIEF FINANCIAL OFFICER 40.00 X 192774 0 30797 STEPHANIE JAMES DIR OF SCIENCE AND GCGH 40.00 X 288174 0 26000 GAIL LEVINE SCIENTIFIC PROGRAM MANAGER 40.00 X 149386 0 26459 KAREN TOUNTAS SCIENTIFIC PROGRAM MANAGER 40.00 X 152591 0 26779 MARIA VASSILEVA SCIENTIFIC PROGRAM MANAGER 40.00 X 136960 0 25216 MICHAEL GOTTLIEB ASSOC DIR OF SCIENCE 40.00 X 234143 0 23414 STEVE HOFFMAN SCIENTIFIC PROGRAM MANAGER 40.00 X 139447 0 25465 2550636 0 335798 14 0 1 0 SWOG CTI 24 FRANK LLOYD WRIGHT DRIVE ANN ARBOR MI 48106 CLINICAL TRIAL 4615196 QUINTILES INC PO BOX 601070 CHARLOTTE NC 28260 PROJECT MANAGEMENT 708038 CCS ASSOCIATES PO BOX 9125 MCLEAN VA 22102 CONSULTING 553140 MARRIOTT BUSINESS SERVICES PO BOX 402642 ATLANTA GA 30384 MEETING SERVICES 404683 THE REGENTS OF THE UNIV OF CALIFORNIA 9500 GILMAN DRMAIL CODE 0009 LA JOLLA CA 92093 PROJECT MANAGEMENT 399943 19 500000 73405546 73905546 ADMINISTRATIVE FEES 561000 197177 197177 197177 214303 214303 71282940 71348725 -65785 -65785 -65785 184675 139378 45297 45297 MISCELLANEOUS REVENUE 541700 153956 153956 153956 74450494 197177 0 347771 35152112 35152112 219718 219718 21969154 21969154 1940876 755061 1182716 3099 2746045 1832409 835201 78435 458277 242342 202254 13681 417301 254925 155401 6975 305673 142660 163013 338998 335915 3083 53500 53500 15000 15000 23251 13711 9463 77 150255 49561 95593 5101 437715 183785 253930 1390625 1322824 67054 747 26542 26542 171874 123196 48678 PROGRAM CONTRACTS 6384946 6384946 CONSULTANTS 1502514 1234372 264269 3873 RECRUITING 154967 63840 91127 SERVICE CHARGES 98342 24582 73760 119807 13574 92205 14028 74077492 70333687 3617789 126016 21557709 20242543 10917910 19827866 243935 101522 662633 608297 32016 54336 68829475 58789274 101581045 99015541 3735752 1338401 5340739 4605461 1196132 1338837 170004 163461 10442627 7446160 X 11306798 11758572 76604220 76594675 3227400 3216134 91138418 91569381 101581045 99015541 373002 57961 0 X X 0 1 X 1 0 X 61850631 59279254 58355026 58635001 73405546 311525458 500000 486000 514000 500000 500000 2500000 62350631 59765254 58869026 59135001 73905546 314025458 159928420 154097038 173991 134140 140900 213728 214303 877062 314902520 2742095 0.48930 0.54000 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 2 4230 3100 4925017 1 1 0 1 X 3381374 6271975 11641 48330 9616660 3491739 14559 -83704 41220 3381374 3498900 15153 25879 48193 3491739 3558830 3214 -91 63053 3498900 3736712 9744 -108391 131734 79235 3558830 0.65000 0.33000 0.02000 0 0 662633 608297 54336 54336 BOND MUTUAL FUNDS 591522 F EQUITY MUTUAL FUNDS 269535 F CORPORATE BONDS 213211 F GOVERNMENT BONDS 56897792 F STOCKS 703404 F EXCHANGE TRADED FUNDS 113810 F 58789274 CHARITABLE GIFT ANNUITY 163461 163461 X 76561089 57961 188637 1724619 1971217 74589872 -139378 -139378 74450494 76130126 188637 1863997 2052634 74077492 0 74077492 PART IV, LINE 2B: AS OF 12/31/2014, THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH, INC HELD $1,338,837 IN AGENCY FUNDS FOR FUTURE DISTRIBUTIONS TO THE NATIONAL INSTITUTES OF HEALTH (NIH). THESE FUNDS ARE DESIGNATED BY THE FUNDER(S) FOR SPECIFIC PROJECTS AT THE NIH, AND WILL BE DISBURSED AS NEEDED. PART V, LINE 4: THE FOUNDATION'S ENDOWMENTS CONSIST OF INDIVIDUAL DONOR-RESTRICTED ENDOWMENT FUNDS ESTABLISHED FOR A VARIETY OF PURPOSES. (E.G. VARIETY OF RESEARCH AND EDUCATIONAL INITIATIVES AT THE FOUNDATION FOR THE NIH). NET ASSETS ASSOCIATED WITH ENDOWMENT FUNDS ARE CLASSIFIED AND REPORTED BASED ON THE EXISTENCE OR ABSENCE OF DONOR-IMPOSED RESTRICTIONS. PART X, LINE 2: THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE; ACCORDINGLY, THE ACCOMPANYING FINANCIAL STATEMENTS DO NOT REFLECT A PROVISION OR LIABILITY FOR FEDERAL AND STATE INCOME TAXES. THE FOUNDATION HAS DETERMINED THAT IT DOES NOT HAVE ANY MATERIAL UNRECOGNIZED TAX BENEFITS OR OBLIGATIONS AS OF DECEMBER 31, 2014 AND 2013. FISCAL YEARS ENDING ON OR AFTER DECEMBER 31, 2011 REMAIN SUBJECT TO EXAMINATION BY FEDERAL AND STATE TAX AUTHORIES. PART XI, LINE 2D - OTHER ADJUSTMENTS: IN KIND CONTRIBUTIONS PART XI, LINE 4B - OTHER ADJUSTMENTS: FUNDRAISING DIRECT EXPENSE PART XII, LINE 2D - OTHER ADJUSTMENTS: IN KIND CONTRIBUTIONS FUNDRAISING DIRECT EXPENSE 1 EAST ASIA AND THE PACIFIC 0 0 GRANTMAKING 11010529 EUROPE 0 0 GRANTMAKING 10434252 SUB-SAHARAN AFRICA 0 0 GRANTMAKING 210453 SOUTH ASIA 0 0 GRANTMAKING 313920 0 0 0 0 0 0 21969154 0 21969154 EUROPE DEVELOP A GENETIC STRATEGY TO DEPLETE OR INCAPACITATE INSECTS/VIMC2 9416510 WIRE TRANSFER SOUTH ASIA EPIDEMIOLOGY OF VISCERAL LEISMANIASIS PROJECT 95211 WIRE TRANSFER EAST ASIA AND THE PACIFIC MODIFYING MOSQUITO POPULATION AGE STRUCTURE TO ELIMINATE DENGUE TRANSMISSION-ELIMINATE DENGUE 10995461 WIRE TRANSFER SOUTH ASIA EPIDEMIOLOGY OF VISCERAL LEISMANIASIS PROJECT 218709 WIRE TRANSFER EUROPE IDENTIFICATION OF HIGH-QUALITY HITS FOR TUBERCULOSIS 477592 WIRE TRANSFER EAST ASIA AND THE PACIFIC BIOMARKERS OSTEOARTHRITIS 15068 WIRE TRANSFER SUB-SAHARAN AFRICA IDENTIFICATION OF HIGH-QUALITY HITS FOR TUBERCULOSIS 210453 WIRE TRANSFER EUROPE IDENTIFICATION OF HIGH-QUALITY HITS FOR TUBERCULOSIS 540150 WIRE TRANSFER 8 0 0 0 0 0 0 PART I, LINE 2: PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS SOME DEVELOPING COUNTRY INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. 2014- FNIH AWARD CEREMONY 184675 184675 17422 121956 184675 184675 17422 121956 139378 45297 1 NIHNIA 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 13050991 RESEARCH NIHNIAID 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 4072380 RESEARCH NIHNHLBI 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 4050877 RESEARCH NIHNIAMS 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 3000000 RESEARCH NIHNINDS 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 2858899 RESEARCH JOHNS HOPKINS UNIVERSITY 615 N WOLFE ST W1100 BALTIMORE MD 21205 150595110 501(C)(3) 1266704 MAL-ED NIH- CLINICAL CENTER 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 1033784 RESEARCH NIHNCI 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 835326 RESEARCH UNIVERSITY OF CALIFORNIA SAN FRANCISCO 1855 FOLSOM STREET/MCB425- BOX 0897 SAN FRANCISCO CA 94143 946036493 501(C)(3) 545000 OSTEOARTHRITIS/BONE QUALITY NIHFIC 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 538507 RESEARCH FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FAIRVIEW AVE N SEATTLE WA 98109 237156071 501(C)(3) 529119 VIMC/INNATE AND MUCOSAL IMMUNITY DISCOVERY TEAM THOMAS JEFFERSON UNIVERSITY 125 SOUTH 9TH ST 2ND FLOOR SHERIDAN BUILDING PHILADELPHIA PA 19107 231352651 501(C)(3) 469870 OVAF NIHNICHD 9001 ROCKVILLE PIKE BETHESDA MD 20893 520858116 170(C)(1) GOVT 464268 RESEARCH COLORADO STATE UNIVERSITY 601 HOWES STREET-2002 CAMPUS DELIVERY FORT COLLINS CO 80523 846000545 170(C)(1) GOVT 435319 MOLECULAR MOSQUITOCIDES: DEVELOPMENT OF AN INNOVATIVE AND ROBUST, PLATFORM-BASED APPROACH FOR SUSTAINABLE INSECTICIDAL CONTROL OF ANOPHELINE MOSQUITOES VACCINE AND GENE THERAPY INSTITUTE FLORIDA 11350 SW VILLAGE PARKWAY THIRD FLOOR PORT ST LUCIE FL 34987 364631835 170(C)(1) GOVT 432016 VIMC/INNATE AND MUCOSAL IMMUNITY DISCOVERY TEAM DUKE UNIVERSITY 2200 WEST MAIN STREET SUITE 820 ERWIN SQUARE PLAZA DURHAM NC 27705 560532129 501(C)(3) 350549 PROFICIENCY TESTING CENTRAL/CECI/BIOMARKERS DONALD DANFORTH PLANT SCIENCE CENTER 975 NORTH WARSON ROAD ST LOUIS MO 63132 311584621 501(C)(3) 278792 REGULATORY DEVELOPMENT FOR HEG-MODIFIED MOSQUITOES NEW YORK BLOOD CENTER 310 EAST 67TH STREET NEW YORK NY 10065 131949477 501(C)(3) 198887 OVAF NIHNIDCD 9002 ROCKVILLE PIKE BETHESDA MD 20894 520858117 170(C)(1) GOVT 195000 RESEARCH BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501(C)(3) 124176 NON HUMAN PRIMATE NEW ASSAY THE HOPE FOUNDATION 24 FRANK LLOYD WRIGHT DR SUITE 3600A ANN ARBOR MI 48106 742655302 501(C)(3) 92446 LUNGMAP BRIGHAM AND WOMEN'S HOSPITAL 1620 TREMONT STREET 3RD FLOOR RM BC 3002 BOSTON MA 02120 042312909 501(C)(3) 89616 EVALUATION OF THE EFFECTS OF FCRN MUTATIONS ON ANTIBODY HALF-LIFE.+ KIDNEY FRIENDS OF CANCER RESEARCH 1800 M STREET NW SUITE 1050 SOUTH WASHINGTON DC 20036 521983273 501(C)(3) 75000 LUNG CANCER PROTOCOL NIHNEI 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 69412 RESEARCH NIHNIEHS 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 50000 RESEARCH NIH- NCCAM 9000 ROCKVILLE PIKE BETHESDA MD 20892 520858115 170(C)(1) GOVT 45000 RESEARCH 26 AWARDS 10 130650 FMV PART I, LINE 2: PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS FOR-PROFIT INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. FELLOWS SELECTED FOR FOUNDATION FELLOWSHIPS ARE SELECTED THROUGH NATIONWIDE AND INTERNATIONAL COMPETITIONS. THE CLINICAL RESEARCH TRAINING PROGRAM (CRTP) IS OPEN TO ALL THIRD YEAR STUDENTS ENROLLED IN MEDICAL OR DENTAL SCHOOLS. THE WOMEN'S HEALTH FELLOWSHIP PROGRAMS ARE OPEN TO DOCTORAL-LEVEL CANDIDATES WITHIN FIVE YEARS OF RECEIPT OF THE DOCTORAL DEGREE. APPLICATIONS, CONTAINING TRANSCRIPTS AND ESSAYS ON THEIR RESEARCH GOALS ARE SUBMITTED AND REVIEWED BY PANELS OF NIH SCIENTISTS WHO MAKE RECOMMENDATIONS FOR SELECTION. POTENTIAL FELLOWS ARE OFTEN BROUGHT TO THE CAMPUS FOR INTERVIEWS AND FINAL SELECTION. THE FOUNDATION'S FELLOWSHIPS ARE OPEN TO PROFESSIONALS WORKING AT VARIOUS STAGES OF THEIR RESEARCH CAREERS. APPLICANTS TO THE NEUROSCIENCE FELLOWSHIP, FOR EXAMPLE, ARE YOUNG SCIENTISTS WHO WILL BENEFIT FROM EXPERIENCE OF CLINICAL AND BASIC SCIENCE RESEARCH. THE DIRECTOR'S FELLOWSHIP IN COMPLEMENTARY AND ALTERNATIVE MEDICINE RESEARCH SEEKS A MORE EXPERIENCED SCIENTIST WHO IS WELL-POSITIONED TO BECOME A LEADER IN THE FIELD OF COMPLEMENTARY ALTERNATIVE MEDICINE. X X X 0 0 0 0 0 0 0 0 0 MARIA FREIRE PHD PRESIDENT 374138 0 0 0 0 0 26000 0 0 0 400138 0 0 0 ANDREA BARUCHIN SR ADVISOR TO PRESIDENT 199343 0 0 0 200 0 19934 0 5316 0 224793 0 0 0 ANN ASHBY DEPUTY EXECUTIVE DIRECTOR 208255 0 0 0 2500 0 21075 0 11520 0 243350 0 0 0 DAVID WHOLLEY DIR RESEARCH PARTNERSHIPS 282391 0 0 0 2500 0 26000 0 11520 0 322411 0 0 0 JULIA WOLF-RODDA DIR DEVELOPMENT 187834 0 0 0 0 0 18783 0 11520 0 218137 0 0 0 JULIE TUNE CHIEF FINANCIAL OFFICER 192274 0 0 0 500 0 19277 0 11520 0 223571 0 0 0 STEPHANIE JAMES DIR OF SCIENCE AND GCGH 288174 0 0 0 0 0 26000 0 0 0 314174 0 0 0 GAIL LEVINE SCIENTIFIC PROGRAM MANAGER 146886 0 0 0 2500 0 14939 0 11520 0 175845 0 0 0 KAREN TOUNTAS SCIENTIFIC PROGRAM MANAGER 152591 0 0 0 0 0 15259 0 11520 0 179370 0 0 0 MARIA VASSILEVA SCIENTIFIC PROGRAM MANAGER 130760 0 0 0 6200 0 13696 0 11520 0 162176 0 0 0 MICHAEL GOTTLIEB ASSOC DIR OF SCIENCE 234143 0 0 0 0 0 23414 0 0 0 257557 0 0 0 STEVE HOFFMAN SCIENTIFIC PROGRAM MANAGER 133447 0 6000 0 0 0 13945 0 11520 0 164912 0 0 0 X 2 1492479 MARKET PRICE 0 0 0 FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION: THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH WAS ESTABLISHED BY THE UNITED STATES CONGRESS TO SUPPORT THE NIH IN ITS MISSION TO IMPROVE HEALTH, BY FORMING AND FACILITATING PUBLIC-PRIVATE PARTNERSHIPS FOR BIOMEDICAL RESEARCH AND TRAINING. THE FOUNDATION BUILDS PARTNERSHIP FOR DISCOVERY AND INNOVATION TO IMPROVE HEALTH. FORM 990, PART III, LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS: PROGRAM ONE - RESEARCH PARTNERSHIPS - IN 2014, THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH CONTINUED TO SUPPORT THE MISSION OF THE NIH, FORGING NEW MODELS OF COLLABORATION FOCUSED ON THE GOAL OF ADVANCING BIOMEDICAL SCIENCE TO IMPROVE LIVES. FNIH INITIATIVES BRING TOGETHER GOVERNMENT AGENCIES, FOUNDATIONS, NON-PROFITS, CORPORATIONS AND ACADEMIA IN A WIDE PORTFOLIO OF PROGRAMS TO UNDERSTAND DISEASE, SUPPORT NIH RESEARCH, ENHANCE GLOBAL HEALTH, DEVELOP THE CAREERS OF YOUNGER RESEARCHERS, RECOGNIZE SCIENTIFIC ACHIEVEMENT, EDUCATE THE PUBLIC ABOUT SCIENCE AND MUCH MORE. AMONG THE FNIH PROGRAMS ARE: ACCELERATING MEDICINES PARTNERSHIP (AMP) NEW MEDICINES THAT SHOW PROMISE IN THE LABORATORY OFTEN DO NOT SUCCEED IN HUMAN TESTING. IN FACT, ABOUT 95 PERCENT FAIL, TYPICALLY LATE IN THE CLINICAL TRIALS PROCESS AFTER MILLIONS OF DOLLARS HAVE BEEN INVESTED. SUCH A HIGH-COST, LOW-REWARD PIPELINE POINTS TO THE NEED FOR A BETTER UNDERSTANDING OF HOW DISEASES DEVELOP AT THE MOLECULAR LEVEL-WHICH IS WHY THE FNIH IS HELPING TO LEAD AN UNPRECEDENTED PARTNERSHIP TO FILL THIS NEED. LAUNCHED IN 2014, THE ACCELERATING MEDICINES PARTNERSHIP (AMP) IS A $230 MILLION, FIVE-YEAR EFFORT JOINING THE FORCES OF THE FNIH, THE NIH AND THE FOOD AND DRUG ADMINISTRATION (FDA) WITH THOSE OF NOT-FOR-PROFIT ORGANIZATIONS AND 10 BIOPHARMACEUTICAL COMPANIES TO DEVISE A RADICALLY NEW APPROACH TO EARLY-STAGE DRUG DEVELOPMENT. THESE COMPANIES HAVE AGREED TO SHARE EXPERTISE, RESOURCES AND DATA TO ANSWER A CRITICAL QUESTION: WHICH BIOLOGICAL PATHWAYS UNDERLYING A GIVEN DISEASE ARE THE BEST CANDIDATES FOR TARGETING NEW TREATMENTS? INSTEAD OF HAVING DIFFERENT ORGANIZATIONS PURSUE DISPARATE PATHWAYS IN ISOLATION, AMP WILL GENERATE PRE-COMPETITIVE, DISEASE-SPECIFIC DATA ON THE GENETIC AND BIOLOGICAL MARKERS MOST LIKELY TO YIELD SUCCESS WHEN USED AS TARGETS FOR NEW MEDICINES. THE DATA WILL BE PUBLICLY AVAILABLE TO THE BIOMEDICAL COMMUNITY SO THAT MANY CAN USE IT AS THE FOUNDATION FOR DRUG DISCOVERY. AMP: TYPE 2 DIABETES MORE THAN 100 MILLION AMERICANS ALREADY HAVE TYPE 2 DIABETES OR ARE AT HIGH RISK, AND 382 MILLION PEOPLE WORLDWIDE HAVE A TYPE 2 DIAGNOSIS. ALTHOUGH THERAPIES ARE AVAILABLE, NONE CAN REVERSE THE DISEASE PROCESS OR PREVENT THE PROGRESSION THAT LEADS TO LIFE-ALTERING COMPLICATIONS SUCH AS CARDIOVASCULAR AND KIDNEY DISEASE, LIMB LOSS AND BLINDNESS. AMP PARTNERS WILL LEVERAGE THE SUBSTANTIAL AMOUNT OF DATA ALREADY AVAILABLE FROM PATIENTS WITH TYPE 2 DIABETES AND THOSE AT HIGH RISK TO IDENTIFY AND VALIDATE DNA REGIONS CRITICAL IN THE DEVELOPMENT OR PROGRESSION OF THE DISEASE, WITH AN EYE TOWARD IDENTIFYING POTENTIAL DRUG TARGETS. AMP: ALZHEIMER'S DISEASE ALZHEIMER'S DISEASE (AD) IS THE MOST COMMON FORM OF DEMENTIA, A CONDITION THAT AFFECTS 36 MILLION PEOPLE GLOBALLY-A NUMBER EXPECTED TO SKYROCKET TO 115 MILLION BY 2050 UNLESS AN EFFECTIVE THERAPY IS DEVELOPED. SCIENTISTS KNOW THAT PEOPLE WITH AD HAVE THE SIGNATURE PROTEIN- BASED BRAIN LESIONS CALLED PLAQUES AND TANGLES; HOWEVER, EFFORTS TO HARNESS THIS KNOWLEDGE TO DEVELOP NEW THERAPIES HAVE NOT SUCCEEDED. AMP PARTNERS ARE WORKING TO ESTABLISH AN EXPANDED SET OF BIOLOGICAL MARKERS THAT ARE PRESENT WHEN AD DEVELOPS, AND THEN DETERMINE WHICH ARE MOST PROMISING FOR DEVELOPING NEW TREATMENTS AND PREDICTING THE LIKELIHOOD OF CLINICAL RESPONSE. THE PROJECT WILL INVOLVE THE LARGE-SCALE ANALYSIS OF BRAIN TISSUE FROM AD PATIENTS AND CLINICAL TRIALS TO VALIDATE NEWLY IDENTIFIED BIOMARKERS. AMP: RHEUMATOID ARTHRITIS & LUPUS RHEUMATOID ARTHRITIS (RA) AND LUPUS ARE JUST TWO OF MANY DISORDERS THAT OCCUR WHEN THE IMMUNE SYSTEM MISTAKENLY ATTACKS PARTS OF THE BODY THAT IT IS DESIGNED TO PROTECT, LEADING TO INFLAMMATION THAT DESTROYS TISSUES. ANTI-INFLAMMATORY TREATMENTS CAN HELP, BUT MOST PEOPLE WITH RA RESPOND TO CURRENT TREATMENTS ONLY PARTIALLY OR TEMPORARILY. IN THE CASE OF LUPUS, NO EFFECTIVE TARGETED THERAPIES EXIST FOR THE MOST SEVERE FORMS OF THE DISEASE. AMP PARTNERS WILL ANALYZE TISSUE AND BLOOD SAMPLES FROM PEOPLE WITH RA AND LUPUS TO PINPOINT GENES, PROTEINS, CHEMICAL PATHWAYS AND NETWORKS INVOLVED AT THE CELLULAR LEVEL. THIS IS ESSENTIAL FOR DEVELOPING TARGETED TREATMENTS FOR THESE DEBILITATING CONDITIONS, BUT IT ALSO COULD SHED LIGHT ON THE AUTOIMMUNE PROCESS IMPLICATED IN A WIDE RANGE OF DISEASES. THE LUNG CANCER MASTER PROTOCOL PATIENTS WITH ADVANCED SQUAMOUS CELL LUNG CANCER HAVE FEW GOOD TREATMENT OPTIONS BEYOND SURGERY, YET THE PACE OF TRADITIONAL CLINICAL TRIALS REMAINS SLOW, WITH MOST POTENTIAL TREATMENTS NEVER MAKING IT TO THE BEDSIDE. THE LUNG CANCER MASTER PROTOCOL (LUNG-MAP) TRIAL, THE RESULT OF A PARTNERSHIP THAT INCLUDES THE FNIH, IS PIONEERING A NEW MODEL DESIGNED TO SPEED ACCESS TO INVESTIGATIONAL DRUGS FOR PATIENTS AND ALLOW MULTIPLE RESEARCHERS TO SHARE ONE UMBRELLA STRUCTURE AND RECRUITMENT PROCESS, SIGNIFICANTLY INCREASING THEIR EFFICIENCY. LAUNCHED IN JUNE 2014, LUNG-MAP USES GENOMIC PROFILING TECHNOLOGY TO TEST PATIENTS FOR OVER 200 CANCER-RELATED GENETIC ALTERATIONS, THEN ASSIGNS THEM TO ONE OF A NUMBER OF INVESTIGATIONAL TREATMENT STUDIES BASED ON THEIR GENETIC PROFILE. WITHIN ITS FIRST SIX MONTHS, LUNG-MAP WAS ENROLLING PATIENTS AT MORE THAN 400 SITES IN 39 STATES. THE TRIAL WILL ADD NEW INVESTIGATIONAL TREATMENTS OVER TIME, WITH THE ULTIMATE GOAL OF TESTING 10 TO 12 TARGETED THERAPIES IN 5,000 PATIENTS OVER THE NEXT FIVE YEARS. BESIDES THE FNIH, PARTNERS IN THE EFFORT INCLUDE THE NATIONAL CANCER INSTITUTE, SWOG CANCER RESEARCH, FRIENDS OF CANCER RESEARCH, FOUNDATION MEDICINE, FIVE PHARMACEUTICAL COMPANIES AND SEVERAL LUNG CANCER ADVOCACY GROUPS. CONSENSUS DEFINITION OF CLINICALLY IMPORTANT SARCOPENIA. SARCOPENIA-AGE-RELATED MUSCLE LOSS AND WEAKNESS-AFFECTS NEARLY 1 IN 3 PEOPLE OVER 60 AND HALF OF THOSE OVER AGE 80. HOWEVER, LACK OF AN EVIDENCE-BASED DEFINITION FOR SARCOPENIA HAS LIMITED OUR ABILITY TO UNDERSTAND ITS PROGRESSION AND DEVELOP STRATEGIES FOR PREVENTION AND TREATMENT. THIS CHANGED IN APRIL 2014 WITH THE LANDMARK PUBLICATION OF SIX SPECIAL ONLINE ARTICLES IN THE JOURNALS OF GERONTOLOGY: MEDICAL SCIENCES, WHICH SET FORTH DATA-DRIVEN DIAGNOSTIC CRITERIA FOR SARCOPENIA, INCLUDING DEFINITIONS OF GRIP STRENGTH AND MUSCLE MASS. THE ARTICLES RESULTED FROM A COLLABORATIVE PROJECT BY THE FNIH BIOMARKERS CONSORTIUM, THE FDA, THE NATIONAL INSTITUTE ON AGING AND SEVERAL PHARMACEUTICAL COMPANIES, IN WHICH RESEARCHERS ANALYZED DATA FROM NINE LONG-TERM EPIDEMIOLOGIC STUDIES INVOLVING OVER 26,000 HEALTHY PARTICIPANTS TO GENERATE A DEFINITION OF SARCOPENIA. IN ADDITION TO DIAGNOSTIC CRITERIA, THE 2014 PUBLICATIONS PROVIDE SPECIFIC CHARACTERIZATIONS OF HOW LOW LEAN MASS AND LOW STRENGTH RELATE TO PROBLEMS WITH MOBILITY. THIS NEW INFORMATION IS EXPECTED TO INFLUENCE TREATMENT DECISIONS AND HELP IDENTIFY GROUPS OF AT-RISK PATIENTS WHO ARE GOOD CANDIDATES FOR TESTING INTERVENTIONS. RIVER BLINDNESS: MOVING BEYOND CONTROL TO ELIMINATION OVER THE PAST FEW DECADES, FOCUSED EFFORTS TO CONTROL THE TROPICAL DISEASE ONCHOCERCIASIS, OR RIVER BLINDNESS, HAVE DRASTICALLY LOWERED INCIDENCE IN SOUTH AND CENTRAL AMERICA, BUT THE DISEASE CONTINUES TO HAVE A DEVASTATING IMPACT IN SUB-SAHARAN AFRICA. RIVER BLINDNESS IS CAUSED BY ONCHOCERCA VOLVULUS WORMS, WHICH ARE TRANSMITTED TO HUMANS THROUGH REPEATED BITES FROM INFECTED BLACKFLIES. MASS ADMINISTRATION OF THE DRUG IVERMECTIN IS AN EFFECTIVE CONTROL STRATEGY, BUT IT DOES NOT GUARANTEE ELIMINATION OF THE DISEASE FROM A POPULATION, AS PEOPLE CAN CARRY THE WORMS WITHOUT EXHIBITING SYMPTOMS. THE FNIH IS WORKING WITH THE NIAID TO DETERMINE IF A BLOOD OR URINE TEST COULD BE DEVELOPED TO IDENTIFY PEOPLE WHO ARE CARRIERS OF ADULT FEMALE ONCHOCERCA VOLVULUS WORMS (OVAF). ONCE INSIDE A HUMAN HOST, THESE FEMALES PRODUCE SMALLER LARVAE THAT OVER TIME CAN CAUSE CHRONIC SKIN DISEASE, SEVERE ITCHING AND EYE LESIONS THAT LEAD TO BLINDNESS. KNOWING IF SOMEONE IS A CARRIER WOULD ENSURE THEY COULD BE TREATED AND PREVENT TRANSMISSION OF THE WORMS TO UNINFECTED BLACKFLIES. THE FNIH AND NIAID ARE STUDYING OVAF AND OVAF-INFECTED HUMANS TO IDENTIFY BIOMARKERS IN BLOOD AND URINE THAT MIGHT INDICATE THE PRESENCE OF THE FEMALE WORM, AND THEN TEST AND VALIDATE THE MOST PROMISING CANDIDATES. THE ULTIMATE GOAL IS A POINT-OF-CARE TEST THAT WOULD HELP ERADICATE RIVER BLINDNESS AROUND THE GLOBE. FORM 990, PART III, LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS: THE WORK OF THE FNIH ALSO INCLUDES INITIATIVES AND STUDIES IN NUMEROUS OTHER AREAS, INCLUDING: ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE AS THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI) APPROACHES THE END OF ITS FIRST DECADE, THE PARTNERSHIP REMAINS A GOLD STANDARD FOR HOW ACADEMIC, INDUSTRY, ADVOCACY AND GOVERNMENT PARTNERS CAN, TOGETHER, ADVANCE BIOMEDICAL RESEARCH. INVOLVING MORE THAN 25 PARTNERS COORDINATED BY FNIH, ADNI CREATED AN ONLINE, OPEN-ACCESS DATABASE AND IMAGE ARCHIVE FOR ALL INFORMATION COLLECTED BY RESEARCHERS. IN ADNI PHASE 1, THE STUDY PERFORMED MRI AND PET SCANS AND COLLECTED CEREBROSPINAL FLUID AND OTHER BIOSAMPLES FROM 1,500 PARTICIPANTS. PHASE 2, WHICH WILL CONTINUE THROUGH 2015, FOLLOWS PHASE 1 PARTICIPANTS AND HAS ENROLLED AN ADDITIONAL 750 PEOPLE. THE STUDY HAS ALSO EXPANDED TO INCLUDE GENETIC TESTING, INCLUDING WHOLE-GENOME SEQUENCING FOR MORE THAN 800 PARTICIPANTS. SPIROMICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), WHICH INCLUDES CHRONIC BRONCHITIS AND EMPHYSEMA, AFFECTS MORE THAN 12 MILLION AMERICANS AND IS THE COUNTRY'S THIRD LEADING CAUSE OF DEATH. THE DISEASE PROGRESSES OVER TIME, SUGGESTING THAT THERE MAY BE POINTS FOR EARLY INTERVENTION TO PREVENT FULL-BLOWN COPD FROM DEVELOPING. HOWEVER, WE DO NOT UNDERSTAND THE DISEASE'S CLINICAL COURSE WELL ENOUGH TO MAKE THAT HAPPEN. THE SPIROMICS (SUBPOPULATIONS AND INTERMEDIATE OUTCOME MEASURES IN COPD STUDY) PROGRAM BRINGS TOGETHER THE NATIONAL HEART, LUNG AND BLOOD INSTITUTE, THE FOOD AND DRUG ADMINISTRATION, INDUSTRY PARTNERS AND MULTIPLE RESEARCHERS ACROSS THE COUNTRY. THE STUDY IS ENROLLING SUBJECTS WITH COPD AT 11 SITES NATIONALLY AND COLLECTING BLOOD SAMPLES, IMAGES, LUNG FUNCTION TESTS AND GENETIC INFORMATION. FNIH COORDINATES THE SPIROMICS EXTERNAL SCIENTIFIC BOARD. GLOBAL HEALTH COLLABORATING WITH ORGANIZATIONS AROUND THE WORLD, FNIH FURTHERS THE UNDERSTANDING AND CONTROL OF DISEASES THAT SICKEN AND KILL HUNDREDS OF MILLIONS OF PEOPLE EVERY YEAR. WORKING IN THE U.S. AND INTERNATIONALLY, FNIH-FUNDED INVESTIGATORS ARE MAKING STRIDES AGAINST LIFE-THREATENING DISEASES INCLUDING MALARIA, DENGUE, TUBERCULOSIS, ENTERIC INFECTIONS AND MALNUTRITION. GRAND CHALLENGES IN GLOBAL HEALTH FOUND IN 100 COUNTRIES, WITH NO VACCINE AND NO CURE, THE MOSQUITO-BORNE VIRAL DISEASE KNOWN A DENGUE FEVER IS A SIGNIFICANT GLOBAL HEALTH THREAT. USING INSECTICIDES TO CONTROL POPULATIONS OF THE FEMALE AEDES AEGYPTI MOSQUITO, WHICH SPREADS THE VIRUS, HAS FAILED TO STOP DENGUE; IN FACT, INCIDENCE HAS INCREASED 30-FOLD IN THE LAST 50 YEARS. THE FNIH'S GRAND CHALLENGES IN GLOBAL HEALTH, AN INITIATIVE FUNDED BY THE BILL & MELINDA GATES FOUNDATION, IS SUPPORTING A GLOBAL NETWORK OF RESEARCHERS WHO HAVE FOUND THAT INFECTING THE MOSQUITOES WITH WOLBACHIA, A COMMON BACTERIUM FOUND IN MANY INSECTS, CAN REDUCE MOSQUITOES' ABILITY TO TRANSMIT THE VIRUS. THE METHOD, WHICH HAS SHOWN GREAT PROMISE THROUGH A SERIES OF TEST RELEASES, IS PART OF ELIMINATE DENGUE, ONE OF SEVERAL PROJECTS THAT ARE PART OF THE FNIH'S VECTOR-BASED CONTROL OF TRANSMISSION: DISCOVER RESEARCH (VCTR) PROGRAM, AN OFFSHOOT OF THE GRAND CHALLENGES INITIATIVE. MAL-ED THE $40 MILLION MAL-ED NETWORK, A COLLABORATIVE PROJECT SUPPORTED BY THE BILL & MELINDA GATES FOUNDATION AND MANAGED BY THE FNIH IN COOPERATING WITH THE NIH FOGARTY INTERNATIONAL CENTER, SUPPORTS RESEARCHERS AT EIGHT FIELD SITES IN AFRICA, ASIA AND SOUTH AMERICA, WHO HAVE BEEN FOLLOWING MORE THAN 1,600 CHILDREN SINCE BIRTH, TO UNDERSTAND HOW ENTERIC PATHOGENS, NUTRITION AND OTHER ENVIRONMENTAL FACTORS ARE LINKED TO PHYSICAL GROWTH, COGNITIVE DEVELOPMENT AND VACCINE RESPONSE. IDENTIFYING BIOMARKERS THAT PREDICT GROWTH FALTERING AND/OR IMPAIRED COGNITIVE DEVELOPMENT WILL INFORM DEVELOPMENT OF STRATEGIES FOR TIMELY INTERVENTION. FORM 990, PART III, LINE 4B, PROGRAM SERVICE ACCOMPLISHMENTS: PROGRAM TWO - FELLOWSHIPS AND TRAINING PROGRAMS - WHILE TECHNOLOGY PLAYS AN INCREASINGLY VITAL ROLE IN ADVANCING HUMAN HEALTH, PROGRESS IS IMPOSSIBLE WITHOUT A NEW GENERATION OF CAPABLE AND CURIOUS RESEARCHERS. FNIH PROGRAMS IN VARIOUS FORMATS TARGET A WIDE ARRAY OF TOPICS AND EDUCATION LEVELS, MAKING THE WORLD-CLASS METHODS AND RESOURCES OF THE NIH AVAILABLE TO STUDENTS AND RESEARCHERS ALL OVER THE WORLD. EXAMPLES INCLUDE: MEDICAL RESEARCH SCHOLARS PROGRAM. THE MEDICAL RESEARCH SCHOLARS PROGRAM BRINGS TO THE NIH CAMPUS SOME OF THE BEST AND BRIGHTEST YOUNG RESEARCHERS FROM MEDICAL, DENTAL AND VETERINARY SCHOOLS ACROSS THE COUNTRY. DURING THE YEAR-LONG PROGRAM, THE STUDENTS CONDUCT BASIC, TRANSLATIONAL OR CLINICAL RESEARCH IN A FIELD OF THEIR CHOICE, GUIDED BY A MENTOR AND A TUTOR. THE PROGRAM IMMERSES STUDENTS IN BIOMEDICAL RESEARCH EARLY IN THEIR CAREER TRAINING. IN ADDITION TO THEIR RESEARCH WORK, STUDENTS COMPLETE AN ACADEMIC CURRICULUM AND INTERACT WITH NIH SCIENTIFIC LEADERS, INCLUDING INSTITUTE DIRECTORS, CLINICAL DIRECTORS AND ESTABLISHED INVESTIGATORS. THE PROGRAM MERGES AND BUILDS ON TWO EARLIER, HIGHLY SUCCESSFUL TRAINING PROGRAMS, THE HOWARD HUGHES MEDICAL INSTITUTE-NIH RESEARCH SCHOLARS PROGRAM AND THE CLINICAL RESEARCH TRAINING PROGRAM. THE GOAL IS TO SUPPORT 70 SCHOLARS EACH YEAR. HUMAN GENOME EXHIBITION. BETWEEN JUNE 2013 AND AUGUST 2014, ROUGHLY THREE MILLION SMITHSONIAN VISITORS EXPERIENCED GENOME: UNLOCKING LIFE'S CODE AT THE NATIONAL MUSEUM OF NATURAL HISTORY, AN EXHIBITION MADE POSSIBLE THROUGH FUNDS RAISED, IN PART, BY THE FNIH. THE RESULT OF A COLLABORATION BETWEEN THE MUSEUM AND THE NATIONAL HUMAN GENOME RESEARCH INSTITUTE, GENOME AWED VISITORS WITH THE COMPLEXITY AND POWER OF THE HUMAN GENOME USING 3-D MODELS, INTERACTIVE DISPLAYS, CUSTOM ANIMATIONS AND VIDEOS OF REAL-LIFE STORIES. IT CELEBRATED THE 10TH ANNIVERSARY OF THE HUMAN GENOME PROJECT AND THE SUCCESSFUL SEQUENCING OF THE HUMAN GENETIC BLUEPRINT, HELPING VIEWERS UNDERSTAND HOW THIS KNOWLEDGE IS REVOLUTIONIZING OUR UNDERSTANDING OF HUMAN DEVELOPMENT, DIVERSITY AND SOCIETY, ESPECIALLY HEALTH AND DISEASE. IN ADDITION TO THE 4,400-SQUARE-FOOT EXHIBITION ITSELF, WHICH TOOK TWO YEARS FOR MUSEUM DESIGNERS AND EDUCATORS TO DEVELOP AND BUILD, GENOME INCLUDED PUBLIC EVENTS, EDUCATIONAL SYMPOSIA, AN EDUCATORS' GUIDE AND THE WEBSITE WWW.UNLOCKINGLIFESCODE.ORG. GENOME IS NOW ON A MULTI-CITY TOUR THAT WILL TAKE IT TO MUSEUMS IN CALIFORNIA, THE MIDWEST AND ONTARIO THROUGH EARLY 2018. HONORS. WHAT IF WE COULD REMOVE AND REPLACE DAMAGED OR DEFECTIVE PARTS OF HUMAN DNA? SCIENTISTS HAVE BEEN WORKING TO FIND SUCH A GENOME-EDITING TOOL, BUT JENNIFER DOUDNA, PH.D., PROFESSOR OF BIOCHEMISTRY, BIOPHYSICS AND STRUCTURAL BIOLOGY AND A HOWARD HUGHES MEDICAL INSTITUTE INVESTIGATOR AT THE UNIVERSITY OF CALIFORNIA, BERKELEY, STANDS APART. DR. DOUDNA HAS FOCUSED HER RESEARCH ON THE STRUCTURE OF RNA, THE MOLECULE THAT CARRIES OUT DNA INSTRUCTIONS FOR CREATING THE PROTEINS THAT DRIVE PROCESSES IN THE BODY. THE FNIH AWARDED HER THE LURIE PRIZE IN BIOMEDICAL SCIENCES IN 2014 FOR THAT BODY OF STUDY, WHICH INCLUDES HER WORK ON CRISPR (CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS), THAT ARE REPETITIVE RNA SEQUENCES IN BACTERIA THAT PLAY A ROLE IN THEIR IMMUNITY. DOUDNA DISCOVERED THAT PIECES OF CRISPR RNA TEAM UP WITH A PROTEIN CALLED CAS9 TO CUT THROUGH THE DNA OF AN INVADING VIRUS. DOUDNA AND HER TEAM THEN ENGINEERED THEIR OWN RNA/PROTEIN COMBINATION AND SHOWED IT CAN BE USED TO PRECISELY EDIT THE DNA OF PLANTS, ANIMALS AND HUMANS. THIS CRISPR TOOL HAS TO BE MANAGED WITH CAREFUL ATTENTION TO BIOETHICAL CONCERNS, BUT IT COULD FUNCTION AS "MOLECULAR SCISSORS" THAT CAN FIX FAULTY GENES UNDERLYING A RANGE OF DISEASES AND HEALTH CONDITIONS. FORM 990, PART III, LINE 4C, PROGRAM SERVICE ACCOMPLISHMENTS: PROGRAM THREE - CAPITAL PROJECTS - THE FOUNDATION'S CAPITAL PROJECTS ENHANCE THE RESEARCH ENVIRONMENT AT NIH, SUPPORTING AND PROMOTING THE IMPORTANT DISCOVERIES THAT RESULT FROM NIH'S LEADING-EDGE WORK. THE EDMOND J. SAFRA FAMILY LODGE, FOR EXAMPLE, OPENED IN 2005 TO SERVE AS A COMFORTABLE HOME-AWAY-FROM-HOME FOR FAMILIES THAT COME TO NIH'S CAMPUS IN BETHESDA, MARYLAND TO ACCOMPANY PATIENTS WHO ARE PARTICIPATING IN CLINICAL TRIALS OR RECEIVING TREATMENT AT NIH'S CLINICAL CENTER. SO FAR, THE LODGE HAS HOSTED MORE THAN 40,000 FAMILY MEMBERS AND CAREGIVERS OF ADULT PATIENTS FROM ALL OVER THE WORLD. FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES: MEMORIALS, AWARDS AND EVENTS - COLLABORATION HAPPENS WHEN PEOPLE CONNECT. THAT IS WHY MANAGING AND ORGANIZING MEETINGS AND EVENTS IS FUNDAMENTAL TO THE WORK OF THE FNIH. FROM LECTURES AND WORKSHOPS TO COLLABORATIVE SUMMITS, TELECONFERENCES AND MEDIA OPPORTUNITIES, THE FNIH FACILITATED MORE THAN 60 EVENTS IN 2014 - SPANNING THE GLOBE AND DOZENS OF FIELDS OF RESEARCH. FORM 990, PART VI, SECTION B, LINE 11 PRIOR TO THE SUBMISSION OF THE FOUNDATION FOR NIH'S FORM 990 TO THE INTERNAL REVENUE SERVICE, EACH VOTING MEMBER OF THE BOARD OF DIRECTORS SHALL BE PROVIDED WITH A COPY OF THE FINAL FORM 990 AS COMPLETED BY THE CHIEF FINANCIAL OFFICER. BOARD DIRECTORS SHALL BE PROVIDED WITH AT LEAST TEN BUSINESS DAYS TO REVIEW THE FORM AND RAISE QUESTIONS, MAKE SUGGESTIONS, AND ADDRESS ANY POTENTIAL PROBLEMS OR CONCERNS WITH THE CHIEF FINANCIAL OFFICER. A SPECIAL MEETING OF THE GOVERNANCE COMMITTEE WILL BE CALLED TO REVIEW THE SUGGESTED CHANGES FROM THE BOARD OF DIRECTORS AND TO APPROVE THE FINAL VERSION OF THE FORM 990 FOR SUBMISSION. FORM 990, PART VI, SECTION B, LINE 12C THE FOUNDATION REQUIRES DIRECTORS, OFFICERS, VOLUNTEER COMMITTEE MEMBERS, AND STAFF MEMBERS TO DISCLOSE REAL AND APPARENT CONFLICTS OF INTEREST FOR THEMSELVES AND THEIR FAMILY MEMBERS AND TO ANNUALLY SIGN A STATEMENT OF COMPLIANCE. AFTER A CONFLICT OR AN APPARENT CONFLICT OF INTEREST HAS BEEN DISCLOSED, THE BOARD OF DIRECTORS OR THE BOARD COMMITTEE, OR THEIR DESIGNEE, IN THE ABSENCE OF THE INTERESTED PERSON, SHALL DETERMINE IF THE CONFLICT OF INTEREST OR THE APPEARANCE OF A CONFLICT OF INTEREST EXISTS AND IS MATERIAL AND WILL DECIDE HOW IT IS TO BE MANAGED OR ELIMINATED. FORM 990, PART VI, SECTION B, LINE 15 BEGINNING IN 2015, THE NEWLY CREATED COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS WILL REVIEW AND APPROVE THE SALARIES OF THE EXECUTIVE DIRECTOR AND KEY EMPLOYEES ANNUALLY. FORM 990, PART VI, SECTION C, LINE 19 ALL DOCUMENTS ARE AVAILABLE UPON REQUEST. THE AUDITED FINANCIAL STATEMENTS ARE POSTED TO THE ORGANIZATION'S WEBSITE. FORM 990, PART XII, LINE 2C: PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.